PARDES BIOSCIENCES, INC.
PARDES BIOSCIENCES, INC. (PRDS): 1 pipeline candidate · ~23 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.9 months
D/E 0.01 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for PARDES BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$100.3M
Quarterly Burn
$19.9M
Runway
22.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| pomotrelvir | Phase 2 |
Frequently asked questions
How many drug candidates are in PARDES BIOSCIENCES, INC.'s pipeline?
PARDES BIOSCIENCES, INC. (PRDS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is PARDES BIOSCIENCES, INC.'s lead drug candidate?
PARDES BIOSCIENCES, INC.'s most advanced tracked candidate is pomotrelvir (Phase 2) for COVID-19.
What is PARDES BIOSCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PARDES BIOSCIENCES, INC. has approximately 22.9 months of cash runway.
Who is the CEO of PARDES BIOSCIENCES, INC.?
Thomas G. Wiggans is the chief executive officer of PARDES BIOSCIENCES, INC. (PRDS).
Get the full picture on PARDES BIOSCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.